Onconetix, Inc. (NASDAQ:ONCO – Get Free Report) was the recipient of a significant decline in short interest during the month of October. As of October 15th, there was short interest totalling 20,300 shares, a decline of 94.6% from the September 30th total of 375,300 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average daily trading volume, of 676,600 shares, the days-to-cover ratio is presently 0.0 days.
Hedge Funds Weigh In On Onconetix
An institutional investor recently bought a new position in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Onconetix, Inc. (NASDAQ:ONCO – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 306,079 shares of the company’s stock, valued at approximately $51,000. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 1.37% of Onconetix as of its most recent SEC filing. Hedge funds and other institutional investors own 23.89% of the company’s stock.
Onconetix Stock Down 4.5 %
ONCO traded down $0.18 during trading hours on Friday, reaching $3.83. The company’s stock had a trading volume of 17,886 shares, compared to its average volume of 336,654. The company’s 50-day moving average is $5.11 and its 200-day moving average is $5.70. Onconetix has a 52 week low of $2.82 and a 52 week high of $21.40.
Onconetix Company Profile
Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
Read More
- Five stocks we like better than Onconetix
- Best Stocks Under $10.00
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- How to Use the MarketBeat Stock Screener
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.
